Volume 7, Issue 11

Newer Options for Treatment-Experienced Patients

In this issue:

For clinicians seeking to provide the most effective HIV management, choosing ART for treatment-experienced patients with resistance-associated mutations may present a significant challenge. If a patient has developed resistance to medications from one or more classes of ART, which agents or combinations of agents are most likely to provide adequate treatment? What place should newer antiretroviral drugs have in the treatment armamentarium? 

These are some of the questions Dr. Brian Wood from the Division of Allergy and Infectious Diseases at the University of Washington in Seattle addresses in this issue of eHIV Review.

Learning objectives:

  • Describe the potential role for the NNRTI doravirine for treatment-experienced individuals, including those with a history of specific NNRTI resistance-associated mutations. 
  • Discuss potential uses of relatively new FDA-approved antiretroviral agents (including fostemsavir and ibalizumab) as part of combination therapy for heavily treatment-experienced individuals with multiclass drug resistance, plus the possible future role of the investigational capsid inhibitor lenacapavir.


Brian Wood, MD
Brian Wood, MD

Associate Professor of Medicine, Division of Allergy and Infectious Diseases
University of Washington
Seattle, WA

Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA

Matthew Spinelli, MD, MAS

Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California

Ethel D. Weld, MD, PhD

Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: September 27, 2022
Expiration date: September 26, 2024